Evropská unie -
řečtina -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Οφθαλμολογικά - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
Řecko -
řečtina -
Εθνικός Οργανισμός Φαρμάκων
dimtruzic® gr.cap 240mg/cap
sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - dimethyl fumarate - gr.cap (ΓΑΣΤΡΟΑΝΘΕΚΤΙΚΟ ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 240mg/cap - dimethyl fumarate 240mg - dimethyl fumarate
Řecko -
řečtina -
Εθνικός Οργανισμός Φαρμάκων
dimtruzic® gr.cap 120mg/cap
sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - dimethyl fumarate - gr.cap (ΓΑΣΤΡΟΑΝΘΕΚΤΙΚΟ ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 120mg/cap - dimethyl fumarate 120mg - dimethyl fumarate
